{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:54:14Z","timestamp":1788998054785,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 149086"],"award-info":[{"award-number":["PJT 149086"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 153157"],"award-info":[{"award-number":["PJT 153157"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Women with a history of gestational diabetes (GDM) frequently have progressive beta\u2010cell dysfunction, which may result in type 2 diabetes. However, there is a paucity of clinical studies on strategies aiming to preserve beta\u2010cell function in this patient population. This trial evaluated whether empagliflozin can preserve beta\u2010cell function and reduce the prevalence of dysglycemia (prediabetes\/diabetes) in women with recent GDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a double\u2010blind, randomized, placebo\u2010controlled trial where 91 women with recent GDM (6\u201336\u2009months postpartum) were randomized 1:1 to either empagliflozin 10\u2009mg\/day or placebo for 48\u2009weeks. Beta\u2010cell function was assessed by Insulin Secretion\u2010Sensitivity Index\u20102 (ISSI\u20102) obtained on an oral glucose tolerance test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary outcome of baseline\u2010adjusted ISSI\u20102 at 48\u2009weeks was not different between the empagliflozin and placebo group (525\u2009\u00b1\u200930.4 vs. 560\u2009\u00b1\u200933.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.43). Additional measures of beta\u2010cell function, insulinogenic index\/HOMA\u2010IR, and \u0394Cpep\n                      <jats:sub>0\u2010120<\/jats:sub>\n                      \/\u0394gluc\n                      <jats:sub>0\u2010120<\/jats:sub>\n                      \u2009\u00d7\u2009Matsuda index also did not differ between the groups. While there was no difference in the secondary outcome of prevalence of dysglycemia at 48\u2009weeks between the arms (empagliflozin 65.7% vs. 48.2% in placebo,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.18), the glucose tolerance worsened in 9.4% of participants in the empagliflozin group as compared to 28% in the placebo group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empagliflozin had no significant effect on beta\u2010cell function in women with recent GDM. Given the sample size evaluated in this trial, the use of SGLT\u20102 inhibitors warrants further study to elucidate their potential impact on T2DM prevention in women with previous GDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                      NCT03215069\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70146","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:51:14Z","timestamp":1758192674000},"page":"7408-7415","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Empagliflozin for the preservation of beta\u2010cell function in women with recent gestational diabetes: A randomized placebo\u2010controlled trial"],"prefix":"10.1111","volume":"27","author":[{"given":"Shamini","family":"Murugavel","sequence":"first","affiliation":[{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mount Sinai Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Retnakaran","sequence":"additional","affiliation":[{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Division of Endocrinology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice S.","family":"Feig","sequence":"additional","affiliation":[{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Division of Endocrinology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-1876","authenticated-orcid":false,"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Division of Endocrinology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-0100","authenticated-orcid":false,"given":"Caroline K.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mount Sinai Hospital  Toronto Ontario Canada"},{"name":"Division of Endocrinology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_2_10_2_1","article-title":"The life course perspective of gestational diabetes: an opportunity for the prevention of diabetes and heart disease in women","volume":"45","author":"Fu J","year":"2022","journal-title":"EClin Med"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1361"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1493"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0521"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0351"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1529"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05994-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14966"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0773"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082572"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01606-x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13590"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16070"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v37i6.22247"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-42-2-222"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1375"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042017-094221"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100139"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.307"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02841.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33867-9"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40287-w"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae594"},{"issue":"1","key":"e_1_2_10_27_1","first-page":"S10","article-title":"Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0772"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13940"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15306"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S003"},{"key":"e_1_2_10_32_1","first-page":"1321","article-title":"Sodium\u2010glucose co\u2010transporter 2 inhibitors and new\u2010onset diabetes in cardiovascular or kidney disease","volume":"46","author":"Ostrominski JW","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:31:13Z","timestamp":1771342273000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/dom.70146"],"URL":"https:\/\/doi.org\/10.1111\/dom.70146","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70146\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70146\/v3\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}